Company news
Rocket Pharmaceuticals, Inc. news in 2024
Rocket Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
December 10, 2024
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 9, 2024
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
November 25, 2024
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
November 17, 2024
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
November 11, 2024
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
November 7, 2024
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
November 6, 2024
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
September 16, 2024
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
September 9, 2024
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
August 4, 2024
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
June 27, 2024
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
May 28, 2024
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 9, 2024
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
May 5, 2024
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
April 1, 2024
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
March 25, 2024
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
February 25, 2024
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
February 12, 2024
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Decks in 2024
- Technical Presentation (November 2024)
Technical · 15 slides · Nov 18, 2024